Updated daily
Drug recalls
Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.
Class IIOngoingDec 19, 2018Valsartan TabletsCGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodiethylamine (NDEA) contained in the API used to manufacture the product.Mylan Pharmaceuticals Inc. · D-0314-2019Class IIOngoingDec 19, 2018Valsartan TabletsCGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodiethylamine (NDEA) contained in the API used to manufacture the product.Mylan Pharmaceuticals Inc. · D-0313-2019Class IIOngoingDec 19, 2018Amlodipine and Valsartan TabletsCGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodiethylamine (NDEA) contained in the API used to manufacture the product.Mylan Pharmaceuticals Inc. · D-0312-2019Class IIOngoingDec 19, 2018Amlodipine and Valsartan TabletsCGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodiethylamine (NDEA) contained in the API used to manufacture the product.Mylan Pharmaceuticals Inc. · D-0311-2019Class IIOngoingDec 19, 2018AmlodipineCGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodimethylamine (NDEA) in product.Teva Pharmaceuticals USA · D-0310-2019Class IIOngoingDec 19, 2018AmlodipineCGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodimethylamine (NDEA) in product.Teva Pharmaceuticals USA · D-0309-2019Class IIOngoingDec 19, 2018AmlodipineCGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodimethylamine (NDEA) in product.Teva Pharmaceuticals USA · D-0308-2019Class IIOngoingDec 19, 2018AmlodipineCGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodimethylamine (NDEA) in product.Teva Pharmaceuticals USA · D-0307-2019Class IIOngoingDec 19, 2018Amlodipine and Valsartan Tablets 10 mg/320 mgCGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodimethylamine (NDEA) in product.Teva Pharmaceuticals USA · D-0306-2019Class IIOngoingDec 19, 2018Amlodipine and Valsartan Tablets 5 mg/320 mgCGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodimethylamine (NDEA) in product.Teva Pharmaceuticals USA · D-0305-2019Class IIOngoingDec 19, 2018Amlodipine and Valsartan Tablets 10 mg/160 mgCGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodimethylamine (NDEA) in product.Teva Pharmaceuticals USA · D-0304-2019Class IIOngoingDec 19, 2018Amlodipine and Valsartan Tablets 5 mg/160 mgCGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodimethylamine (NDEA) in product.Teva Pharmaceuticals USA · D-0303-2019Class IITerminatedDec 19, 2018Westminster Irbesartan TabletsCGMP Deviations: FDA laboratory testing confirmed traces of NDEA impurity in specific lots of Irbesartan.Westminster Pharmaceuticals Llc · D-0302-2019Class IITerminatedDec 19, 2018Westminster Irbesartan TabletsCGMP Deviations: FDA laboratory testing confirmed traces of NDEA impurity in specific lots of Irbesartan.Westminster Pharmaceuticals Llc · D-0301-2019Class IITerminatedDec 19, 2018Westminster Irbesartan TabletsCGMP Deviations: FDA laboratory testing confirmed traces of NDEA impurity in specific lots of Irbesartan.Westminster Pharmaceuticals Llc · D-0300-2019Class IITerminatedDec 19, 2018Thyroid PowderCGMP Deviations: Thyroid Powder has inconsistent levels of the active ingredients levothyroxine and liothyronine.LGM Pharma LLC · D-0296-2019Class IIITerminatedDec 19, 2018Norepinephrine 8 mgIncorrect excipient: Product was compounded in 250 mL 5% Dextrose instead of 250 mL 0.9% Sodium ChlorideQuVa Pharma, Inc. · D-0295-2019Class IITerminatedDec 19, 2018Clopidogrel TabletsFailed dissolution specification -Two additional lots being recalled due to Out-of-Specification results observed for dissolution at 18th month stability testing.Dr. Reddy's Laboratories, Inc. · D-0294-2019Class IITerminatedDec 19, 2018FastStat Topical Hemostat Introductory KitcGMP violations noted during the firm's most recent inspection.CAO Group, Inc. · D-0293-2019Class IITerminatedDec 19, 2018BeeGentle Honey Flavored Topical AnestheticcGMP violations noted during the firm's most recent inspection.CAO Group, Inc. · D-0292-2019Class IITerminatedDec 19, 2018SHEER DesenZ Desensitizing TreatmentcGMP violations noted during the firm's most recent inspection.CAO Group, Inc. · D-0291-2019Class IITerminatedDec 19, 2018fas.TRACT Coagulative Hemostatic GelcGMP violations noted during the firm's most recent inspection.CAO Group, Inc. · D-0290-2019Class ITerminatedDec 12, 2018SODIUM CHLORIDE INJECTIONLabeling Not Elsewhere Classified: Fresenius Kabi is taking this action due to an incorrect statement on the product insert for product codes 918610 and 918620...Fresenius Kabi USA, LLC · D-0299-2019Class ITerminatedDec 12, 2018SODIUM CHLORIDE INJECTIONLabeling Not Elsewhere Classified: Fresenius Kabi is taking this action due to an incorrect statement on the product insert for product codes 918610 and 918620...Fresenius Kabi USA, LLC · D-0298-2019Class IIITerminatedDec 12, 2018Amlodipine and Olmesartan Medoxomil TabletsDiscoloration: This product is being recalled due to a confirmed pharmacist report that tablets from this lot were a pink color instead of cream (peach).Aurobindo Pharma USA Inc. · D-0289-2019Class IIITerminatedDec 5, 2018Clindamycin Phosphate Topical Solution USPFailed Impurities/Degradation Specifications; out of specification results observed for other individual impuritiesAkorn, Inc. · D-1208-2019Class IIOngoingDec 5, 2018Sandoz Losartan Potassium and Hydrochlorothiazide TabletsCGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodiethylamine (NDEA) contained in the API used to manufacture the product above the interim acceptable...Sandoz, Inc · D-0359-2019Class IITerminatedDec 5, 2018Quetiapine Tablets USP 400 mgPresence of Foreign Substance; metal shard found in tabletAscend Laboratories LLC · D-0287-2019Class IITerminatedDec 5, 2018Germ Bloc Health Hand Sanitizer FoamMicrobial Contamination of Non-Sterile Product: Presence of Pseudomonas aeruginosa in productAVKARE Inc. · D-0285-2019Class IIITerminatedDec 5, 2018Nitrofurantoin Monohydrate/Macrocrystals capsulesCross contamination with other products: Product is being recalled due to the potential presence of unrelated ingredients (Benazepril, Haloperidol and Perphenazine).RemedyRepack Inc. · D-0284-2019Class IITerminatedDec 5, 2018INFed (Iron Dextran Injection USP) 100 mg elemental iron/2 mLFailed Stability Specification: out of specification for iron content.Allergan · D-0282-2019Class IITerminatedNov 28, 2018Clopidogrel TabletsFailed Dissolution Specification: Out-of-Specification results were observed for dissolution at 18th month stability testing.Dr. Reddy's Laboratories, Inc. · D-0283-2019Class IITerminatedNov 28, 2018Medi-Stat FoamLabeling: Label mix-up - the label on the product may not match the formula in the bottle.Ecolab Inc · D-0275-2019Class IITerminatedNov 28, 2018Equi-Soft FoamLabeling: Label mix-up - the label on the product may not match the formula in the bottle.Ecolab Inc · D-0274-2019Class IIITerminatedNov 28, 2018Nitrofurantoin Capsules USPCross contamination with other products: This sub-recall is being initiated in support of the recall by the manufacturer (Sandoz) dated 11/1/18, which included lots that...American Health Packaging · D-0273-2019Class IITerminatedNov 28, 2018GSMS Irbesartan TabletsCGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodimethylamine (NDEA) in product.Sciegen Pharmaceuticals Inc · D-0272-2019Class IITerminatedNov 28, 2018GSMS Irbesartan TabletsCGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodimethylamine (NDEA) in product.Sciegen Pharmaceuticals Inc · D-0271-2019Class IITerminatedNov 28, 2018GSMS Irbesartan TabletsCGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodimethylamine (NDEA) in product.Sciegen Pharmaceuticals Inc · D-0270-2019Class IITerminatedNov 28, 2018Westminister Irbesartan TabletsCGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodimethylamine (NDEA) in product.Sciegen Pharmaceuticals Inc · D-0269-2019Class IITerminatedNov 28, 2018Westminister Irbesartan TabletsCGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodimethylamine (NDEA) in product.Sciegen Pharmaceuticals Inc · D-0268-2019